VCA
GTBP icon

Verdence Capital Advisors’s GT Biopharma GTBP Stock Holding History

Verdence Capital Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.88K Hold
12,000
– – ﹤0.01% 658
2026
Q1 		$4.9K Sell
12,000
-1,000
-8% -$546 ﹤0.01% 649
2025
Q4 		$10.2K Buy
+13,000
New +$9.23K ﹤0.01% 653

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Verdence Capital Advisors's GTBP Position: Q2 2026 in Review

Verdence Capital Advisors held its GT Biopharma (GTBP) position steady in Q2 2026 at 12,000 shares worth $5.88K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Verdence Capital Advisors first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.2K in Q4 2025. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Verdence Capital Advisors held 12,000 shares of GT Biopharma worth $5.88K as of Q2 2026.
  • Verdence Capital Advisors left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Verdence Capital Advisors's portfolio in Q2 2026, its #658 holding.
  • Verdence Capital Advisors first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Verdence Capital Advisors's GT Biopharma position peaked at $10.2K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Verdence Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.